Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 48

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 48
---
 with the SEC rules. There is no certainty that the amount determined using a Black-Scholes stock option valuation model would be the value, if any, eventually realized by the NEO. The weighted-average assumptions used to estimate the grant date fair value of options granted in 2024, along with the weighted-average grant date fair value, are shown below: |

52 | 2025 Proxy Statement

| ​ | ​                      |
| ​ | EXECUTIVE COMPENSATION |

| ​                               | ​ | ​ |     ​ | ​ |
| Assumption                      |   | ​ |     ​ | ​ |
| Risk‑free interest rate         |   | ​ |  4.13 | % |
| Average life of options (years) |   | ​ |   5.8 | ​ |
| Volatility                      |   | ​ | 23.29 | % |
| Dividend yield                  |   | ​ |  3.92 | % |
| Fair value per stock option     | ​ | $ | 31.53 | ​ |

| (3) | The compensation reported in this column for 2024 was earned as a performance-based incentive award pursuant to the AbbVie Performance Incentive Plan. Additional information regarding the plan can be found in the “Compensation Plan Elements” section of this proxy statement. |

| (4) | The plan amounts shown below are reported in this column, excluding negative amounts under the AbbVie Pension Plan and the AbbVie Supplemental Pension Plan in accordance with SEC rules. The amounts shown below beside each NEO’s name are for 2024, 2023, and 2022, respectively, as applicable. |

AbbVie Pension Plan R. Michael: $3,402 / $119,233 / $(269,837); R. Gonzalez: $(14,755) / $927 / $(48,867); S. Reents: $31,435 / $90,112 / $(11,195); J. Stewart: $23,084 / $277,907 / $(263,944); A. Saleki-Gerhardt: $76,048 / $190,794 / $(202,627); and T. Richmond $36,076. AbbVie Supplemental Pension Plan R. Michael: $1,669,967 / $2,776,666 / $(1,162,821); R. Gonzalez: $(1,228,397) / $(154,979) / $(3,